Compare Apollo Global Management Ord Shs (APO) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Charles River Laboratories Intl. Inc — how do they compare? Apollo Global Management Ord Shs trades at $138.2 (market cap $82.84B), while Charles River Laboratories Intl. Inc trades at $286.39 (market cap $13.46B). The key difference: Apollo Global Management Ord Shs is far larger — about 6.2× Charles River Laboratories Intl. Inc's market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| APO | CRL | |
|---|---|---|
Market Cap | $82.84B | $13.46B |
Sector | Financials | Health |
52-Week High | $152.70 | $282.00 |
52-Week Low | $100.30 | $145.57 |
Enterprise Value | -$168.65B | $16.30B |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $137.75, up 4.34% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Q2 2026 earnings missed estimates at $2.11 per share versus $2.16 expected, but revenue growth remains robust with record fee-related earnings. Recent news highlights strategic AI infrastructure deals and a $2.6 billion financing agreement with Yankee Global Enterprises.
Outlook is positive with an 82% analyst buy rating and $151.50 consensus price target, implying 10% upside. Risks include expense growth impacting net margins and competitive pressures in asset management. The company's strong capital formation and perpetual capital base support long-term growth, but investors should monitor execution on AI initiatives and interest rate sensitivity.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
